Both ketamine (Spravato) and TMS are available to veterans through VA health care, but they differ sharply in VA coverage consistency, speed, and PTSD evidence — a veteran-specific breakdown of which to ask for first.
Veterans with treatment-resistant depression or PTSD who look into VA mental health care often find two very different options on the table: Spravato (esketamine), a form of ketamine, and TMS (transcranial magnetic stimulation). Both are legally available through VA health care, but they differ in how they work, how fast they act, and how strong the veteran-specific evidence is. This guide compares them side by side for veterans specifically — for the general (non-veteran) comparison, see our ketamine vs TMS guide.
| Factor | Ketamine (Spravato, VA) | TMS (VA) |
|---|---|---|
| VA coverage path | Covered for eligible veterans with treatment-resistant depression under the Mission Act, at VA facilities that offer it. Coverage and copay depend on priority group and location. | Offered at many VA medical centers as a depression treatment; availability and coverage details vary by facility — ask your VA psychiatrist directly. |
| Veteran-specific evidence | Strongest available: a 2021 randomized controlled trial (Feder et al.) tested IV ketamine specifically in veterans and active-duty service members with chronic PTSD and found a statistically significant symptom reduction versus an active control.1 | No trial of comparable size or design has tested TMS specifically in veterans with PTSD. TMS's core evidence base is for major depression in the general population.2 |
| FDA status | Esketamine (Spravato) is FDA-approved for treatment-resistant depression; a Schedule III drug. | FDA-cleared medical device for major depression (2008); not a scheduled drug. Deep TMS also cleared for OCD.3 |
| Session time & schedule | ~2 hours in-office per visit (required monitoring), typically twice weekly for the first month, then tapering. | ~20–40 minutes per session, typically 5 days/week for about 6 weeks (roughly 36 sessions).2 |
| Speed of relief | Fast — many people notice a change within hours to a few days. | Slower — most people notice change after 3–6 weeks of the standard protocol. |
| Condition it targets at the VA | Treatment-resistant depression (FDA indication); used off-label in some VA settings for PTSD-related depressive symptoms. | Major depression (core FDA clearance). Not FDA-cleared for PTSD specifically. |
| Side effects | Short-term dissociation, raised blood pressure, nausea, dizziness during and shortly after dosing. | Scalp discomfort, headache, facial twitching during sessions; rare seizure risk. No systemic drug effects. |
Neither option is automatic — both require a referral and, in practice, depend heavily on what your specific VA facility offers.
Spravato at the VA: requires a diagnosis of treatment-resistant depression (generally defined as inadequate response to two or more antidepressant trials), a referral from a VA psychiatrist, and administration at a certified VA facility under ~2 hours of monitoring per visit. See our full breakdown of ketamine therapy options for veterans, including the VETS nonprofit grant program for veterans whose local VA doesn't offer it.
TMS at the VA: many VA medical centers run a TMS program for major depression, typically after standard antidepressants haven't worked. As with Spravato, not every facility offers it, and wait times vary. Ask your VA mental health team directly whether TMS is available at your facility and what the referral criteria are.
Not sure which to bring up first? Our depression treatment path tool walks through cost, coverage, and speed across ketamine, Spravato, TMS, and other options.
This is the sharpest difference between the two options. Feder et al. (2021, American Journal of Psychiatry) is a randomized controlled trial that specifically enrolled veterans and active-duty service members with chronic PTSD, giving six IV ketamine infusions over three weeks and comparing the result to an active control (midazolam). It found a statistically and clinically significant reduction in PTSD symptoms on the CAPS-5 scale.1 That is the strongest veteran-population RCT evidence either treatment has.
TMS's evidence base is deep for major depression generally — its 2008 FDA clearance rests on multisite randomized trials — but there is no veteran-specific PTSD trial of comparable scale.2 That does not mean TMS doesn't help veterans; VA facilities use it for major depression in veteran patients every day. It means the specific claim "ketamine has the stronger veteran-PTSD evidence" is accurate as of 2026, while "TMS has the stronger veteran-PTSD evidence" would not be.
Many veterans carry both a PTSD diagnosis and a comorbid major depressive episode, which is part of why this comparison gets confusing. Here's the honest breakdown by primary diagnosis:
Ask about Spravato first if your primary diagnosis is treatment-resistant depression, PTSD-related symptoms are prominent, or you need faster relief and can manage the ~2-hour in-office visits. It also has the stronger veteran-specific PTSD trial behind it, even though PTSD use itself is off-label.
Ask about TMS first if you want to avoid a dissociative drug experience, your primary diagnosis is major depression rather than PTSD, and you can commit to near-daily visits for several weeks.
Either way, start with a referral conversation — not every VA facility offers both, so the fastest real path is often whichever one your local VA already runs. If your facility offers neither, the VETS nonprofit grant program is a non-VA option worth knowing about.
Both can be covered, but neither is automatic. The VA covers Spravato (esketamine) for eligible veterans with treatment-resistant depression under the Mission Act, at facilities that offer it. Many VA medical centers separately run a TMS program for major depression. Availability and coverage details vary by facility, so ask your VA psychiatrist directly which one your local VA offers.
For PTSD specifically, ketamine has the stronger veteran-specific evidence: a 2021 randomized controlled trial (Feder et al., American Journal of Psychiatry) tested IV ketamine in veterans and active-duty service members with chronic PTSD and found a significant symptom reduction. TMS has no veteran-PTSD trial of comparable size — its core evidence base is for major depression generally, not PTSD specifically.
Ketamine (Spravato) is faster. Many veterans notice a change within hours to a few days. Standard TMS takes about 3 to 6 weeks of near-daily sessions (roughly 36 sessions total) to reach its full effect.
Yes, in many cases. Since they work through different mechanisms, some VA psychiatrists use one after the other when the first doesn't fully work, or coordinate a combined plan. This should always be managed by the psychiatrist overseeing your care, not self-directed.
Not every VA facility offers both. If yours offers neither, ask about transfer to a VA facility that does, or look into the VETS (Veterans Exploring Treatment Solutions) nonprofit grant program, which funds ketamine and other psychedelic therapy for eligible post-9/11 veterans outside the VA system. See our full <a href="/guides/best-ketamine-therapy-for-veterans">ketamine therapy for veterans guide</a> for details.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.